ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
69.18
-1.67 (-2.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close70.85
Open0.00
Bid1.00 x 200
Ask72.25 x 300
Day's Range68.58 - 71.62
52 Week Range26.30 - 76.29
Volume113,185
Avg. Volume127,001
Market Cap2.878B
Beta1.00
PE Ratio (TTM)N/A
EPS (TTM)-4.64
Earnings DateAug 29, 2017 - Sep 4, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est85.04
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon PTH, a long-acting prodrug of parathyroid hormone (PTH) in development for hypoparathyroidism.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Gladstone Commercial, Old Line Bancshares, Randgold Resources, Turning Point Brands, Capella Education, and Ascendis Pharma A/S — Discovering Underlying Factors of Influence

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gladstone ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ASND earnings conference call or presentation 30-May-18 8:30pm GMT

    Q1 2018 Ascendis Pharma A/S Earnings Call

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Reports First Quarter 2018 Financial Results

    -Continued execution and achievement of planned milestones across three wholly-owned clinical programs in rare endocrine diseases-. -Conference Call Today at 4:30 p.m. Eastern Time-. COPENHAGEN, Denmark, ...

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, May 30, 2018 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2018 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives.

  • ACCESSWIRE2 months ago

    Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Ascendis Pharma A/S (NASDAQ: ASND), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ASND as the Company's latest news hit the wire. On May 08, 2018, the Denmark-based biopharmaceutical Company announced that it has dosed the first subjects in a first-in-human Phase-1 trial of TransCon CNP, a long-acting prodrug of a C-type natriuretic peptide (CNP) in development as a therapeutic option for achondroplasia and potentially for other fibroblast growth factor receptor (FGFR)-related skeletal disorders. Active-Investors.com is currently working on the research report for Audentes Therapeutics, Inc. (NASDAQ: BOLD), which also belongs to the Healthcare sector as the Company Ascendis Pharma.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, announced today that it has dosed the first subjects in a first-in-human phase 1 trial of TransCon CNP, a long-acting prodrug of C-type natriuretic peptide (CNP) in development as a therapeutic option for achondroplasia and potentially for other fibroblast growth factor receptor (FGFR)-related skeletal disorders. The double-blind, randomized, placebo-controlled phase 1 trial will evaluate single ascending doses of TransCon CNP in healthy adult subjects to assess safety, tolerability and pharmacokinetics. “Achondroplasia is a serious condition resulting in extensive comorbidities.

  • GlobeNewswire3 months ago

    Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced an upcoming poster presentation on the phase 1 trial for its TransCon PTH product candidate at the European Congress of Endocrinology (ECE), taking place in Barcelona, Spain, May 19-22. “We are eager to present the latest results from the final multiple ascending dose cohorts from the TransCon PTH phase 1 trial to a new group of endocrinologists,” said Jonathan Leff, M.D., Ascendis Pharma’s Chief Medical Officer.

  • Five Stocks To Buy According To Top Biotech-Focused Funds
    Insider Monkey3 months ago

    Five Stocks To Buy According To Top Biotech-Focused Funds

    Biotechnology is a very interesting industry to invest in, but also very complex. If you are looking for stocks that are most likely to see their value surge, then your best bet would be to start with biotech companies. The industry focuses on development of novel therapies and drugs that can treat various conditions, therefore […]

  • GlobeNewswire3 months ago

    Ascendis Pharma A/S Announces Upcoming Investor Presentations

    COPENHAGEN, Denmark, April 25, 2018-- Ascendis Pharma A/S, a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced ...

  • Reuters3 months ago

    High-profile investors bet on stocks tied to millennials - Sohn Conference

    Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders. John Khoury, founder and managing partner of the $2.7 billion (£1.94 billion) Long Pond Capital hedge fund, revealed a long position in U.S. homebuilder D.R. Horton Inc (DHI.N), which he said should rise as more millennials age into the first-time home buyer market.

  • Reuters3 months ago

    High-profile investors bet on stocks tied to millennials - Sohn Conference

    Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders. John Khoury, founder and managing partner of the $2.7 billion (£1.94 billion) Long Pond Capital hedge fund, revealed a long position in U.S. homebuilder D.R. Horton Inc (DHI.N), which he said should rise as more millennials age into the first-time home buyer market.

  • CNBC3 months ago

    Here are the stock picks from the rising hedge fund stars at Sohn

    The Sohn Investment Conference in New York kicked off Monday with hedge fund managers' picks moving markets. Sohn is the most widely anticipated hedge fund event of the year, where managers volunteer their time and best investment ideas to raise money in the fight against childhood cancer. This year, the conference began with Next Wave Sohn, featuring the "next generation of talent" among hedge fund managers.

  • ACCESSWIRE4 months ago

    Wired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

    Stock Monitor: Ascendis Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 04, 2018 / Active-Investors.com has just released a free research report on Synlogic, Inc. (NASDAQ: SYBX ). If you ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ASND earnings conference call or presentation 28-Mar-18 8:30pm GMT

    Full Year 2017 Ascendis Pharma A/S Earnings Call

  • ACCESSWIRE4 months ago

    Ascendis Pharma A/S to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Ascendis Pharma A/S (NASDAQ: ASND ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 28, 2018 at 4:30 PM Eastern Time. ...